NASDAQ$TBPH
Theravance Biopharma Inc · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Reported financial results for the second quarter of 2020 and provided a business update.
Theravance Biopharma reported revenue of $15.0 million and an operating loss of $72.2 million for the second quarter of 2020. The company's cash, cash equivalents, and marketable securities totaled $438.3 million as of June 30, 2020.
- YUPLERI market share improved despite challenges from COVID-19.
- A hybrid sales model with in-person and remote call options is being implemented.
- Late stage clinical programs for ampreloxetine and TD-1473 are expected to readout in 2021.
- Phase 2 study of TD-0903 for Acute Lung Injury caused by COVID-19 is underway.
Headline financials
Revenue & EPS history
Theravance · Revenue · Quarterly
$15M
Revenue by segment
Theravance · $19.4K total across 1 segment · Q3 2022
- YUPELRI$19.4K—100.0%
Forward guidance
Theravance Biopharma is adapting its sales model and continuing to advance clinical programs despite challenges from the global pandemic. They are tailoring their sales model to a hybrid model and expect both ampreloxetine and TD-1473 programs to readout in 2021.
Tailwinds
- YUPLERI market share improved despite challenges from COVID-19.
- A hybrid sales model with in-person and remote call options is being implemented.
- Late stage clinical programs for ampreloxetine and TD-1473 are expected to readout in 2021.
- Phase 2 study of TD-0903 for Acute Lung Injury caused by COVID-19 is underway.
- Forecast YUPELRI becoming a cash-flow positive brand in the US by the end of 2020
Headwinds
- COVID-19 pandemic continues to be a threat to public health.
- Challenges have resulted in delays in late stage clinical programs for ampreloxetine and TD-1473.
- The pandemic shows no signs of stopping, and Theravance Biopharma expects ongoing challenges as new “hot spots” emerge.
- Expect COVID-19 pandemic to continue to adversely impact business operations and financial results
- Ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the U.S. and in other countries
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2020
-0.4%
Avg return
Earnings day
+1.0%
Avg return
5 days after
+0.5%
Avg return
30 days after
53%
26 / 49 earnings
Positive
+22.6%
Q3 2025
Best reaction
-20.0%
Q2 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +2.9% | +2.0% | — | |
| Q1 2026 | +0.4% | -2.8% | -3.8% | |
| Q3 2025 | +22.6% | +15.3% | +17.2% | |
| Q2 2025 | +4.2% | +14.2% | +20.0% | |
| Q1 2025 | -9.0% | -15.1% | +13.6% | |
| Q4 2024 | +2.1% | +0.2% | +1.7% | |
| Q3 2024 | +6.6% | +4.8% | +8.7% | |
| Q2 2024 | -18.8% | -20.5% | -16.6% | |
| Q1 2024 | +0.1% | -1.0% | -7.9% | |
| Q4 2023 | +7.9% | +5.1% | +0.3% | |
| Q3 2023 | +2.8% | +1.3% | +6.3% | |
| Q2 2023 | -2.1% | +0.2% | -4.0% | |
| Q1 2023 | +0.4% | -0.3% | -1.4% | |
| Q4 2022 | +9.4% | +2.0% | +8.6% | |
| Q3 2022 | +4.0% | +13.2% | +7.4% | |
| Q2 2022 | -5.4% | -2.6% | +1.4% | |
| Q1 2022 | -9.5% | -10.5% | -12.0% | |
| Q4 2021 | +6.3% | +7.8% | +4.0% | |
| Q3 2021 | +7.1% | +12.7% | -2.1% | |
| Q2 2021 | -5.9% | -5.9% | -36.4% | |
| Q1 2021 | -1.5% | -0.6% | -15.6% | |
| Q4 2020 | -3.3% | -8.4% | +10.7% | |
| Q3 2020 | -13.4% | -3.6% | -12.0% | |
| Q2 2020 | -11.9% | -15.8% | -15.8% | |
| Q1 2020 | -2.5% | +3.8% | -6.7% | |
| Q4 2019 | -10.5% | +0.6% | +0.7% | |
| Q3 2019 | +0.9% | +3.3% | +23.3% | |
| Q2 2019 | +6.4% | -0.1% | +10.8% | |
| Q1 2019 | -11.8% | -12.8% | -37.8% | |
| Q4 2018 | +1.0% | -0.5% | -7.0% | |
| Q3 2018 | -1.5% | +7.5% | +14.1% | |
| Q2 2018 | +17.3% | +20.3% | +21.0% | |
| Q1 2018 | +5.4% | +7.2% | +1.1% | |
| Q4 2017 | -8.4% | +0.7% | -15.7% | |
| Q3 2017 | -4.3% | -0.7% | -10.6% | |
| Q2 2017 | -20.0% | -19.3% | +3.8% | |
| Q1 2017 | +1.5% | -4.6% | -3.4% | |
| Q4 2016 | +1.0% | +5.9% | +22.2% | |
| Q3 2016 | +17.6% | +32.1% | +17.6% | |
| Q2 2016 | +3.0% | +6.2% | +15.6% | |
| Q1 2016 | +5.1% | — | — | |
| Q4 2015 | -0.3% | — | — | |
| Q3 2015 | -1.5% | — | — | |
| Q2 2015 | +0.4% | — | — | |
| Q1 2015 | +3.0% | — | — | |
| Q4 2014 | -6.9% | — | — | |
| Q3 2014 | -1.9% | — | — | |
| Q2 2014 | -7.5% | — | — | |
| Q1 2014 | -2.6% | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro